Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/10157
Going beyond serology for stratifying the risk of CMV infection in transplant recipients
Rev Med Virol. 2019 Jan;29(1):e2017.
Knowledge of donor and recipient (D/R) cytomegalovirus (CMV) serostatus is critical for risk stratification of CMV infection and disease in transplant recipients, particularly in the solid organ transplantation (SOT) setting. Despite its broad availability and the success of it use, the risk stratification based on the D/R serostatus is not free of limitations since there are a nondepreciable number of patients that are not accurately categorized by this approach. In fact, up to 20% of seropositive SOT recipients, classically considered at intermediate risk, develop episodes of CMV infection and disease after transplantation. Here, we provide an overview of additional donor and recipient factors that may have utility in identifying patients at risk for post-transplant CMV infection. Specifically, we summarize our current understanding regarding the potential use of use CMV-specific T-cell-mediated immunity, neutralizing antibodies and host genetics that may influence the risk of CMV infection and disease. We provide an overview of the benefits and limitations associated with using these immunological factors in risk stratification and propose specific variables that could be analyzed at the pretransplant evaluation to improve the identification of patients with increased individual susceptibility.
Antibodies, Neutralizing | Antibodies, Viral | Cytomegalovirus | Cytomegalovirus Infections | Disease Susceptibility | Disease Transmission, Infectious | Genetic Predisposition to Disease | Humans | Organ Transplantation | Risk Assessment | Serologic Tests | T-Lymphocytes | Transplant Recipients
Files in this item